Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Provide electronic or written informed consent, either personally or through a legally authorized representative, as permitted by local regulations
Age ≥18 years or legal age of majority if >18 years in the participant's country of residence
Current hospitalization or recently discharged with the primary diagnosis of heart failure
Heart failure signs and symptoms at the time of hospital admission
Diagnosis of type 1 diabetes or prior history of diabetic ketoacidosis
Documented prior history of severe hyperkalemia in the setting of MRA use
Treatment with non-steroidal mineralocorticoid receptor antagonist (MRA) or SGLT2i
Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m² and/or potassium >5.0 mmol/L
Colorado Prevention Center
Lead sponsor
Saint Luke's Mid America Heart Institute
Collaborator
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Collaborator